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To continually evaluate the rapidly evolving evidence base on the role of cardiovascular drugs in 
COVID-19 clinical outcomes (susceptibility to infection, hospitalization, hospitalization length, disease 
severity, and all-cause mortality).  
DESIGN 
Living systematic review and meta-analysis. 
DATA SOURCES 
Eligible publications identified from >500 databases indexed through 31st July 2020 and additional 
studies from reference lists, with planned continual surveillance for at least two years. 
STUDY SELECTION 
Observational and interventional studies that report on the association between cardiovascular drugs 
and COVID-19 clinical outcomes. 
DATA EXTRACTION 
Single-reviewer extraction and quality evaluation (using ROBINS-I), with half the records 
independently extracted and evaluated by a second reviewer. 
RESULTS 
Of 23,427 titles screened, 175 studies were included in the quantitative synthesis. The most reported 
drug classes were angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers 
(ARBs) with ACEI/ARB exposure being associated with higher odds of testing positive for COVID-19 
(pooled unadjusted OR 1.15, 95% CI 1.02 to 1.30). Among patients with COVID-19, unadjusted 
estimates showed that ACEI/ARB exposure was associated with being hospitalized (OR 2.25, 1.70 to 
2.98) and having severe disease (OR 1.50, 1.27 to 1.77) but not with the length of hospitalization (mean 
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difference -0.45, -1.33 to 0.43 days) or all-cause mortality (OR 1.25, CI 0.98 to 1.58).  However, after 
adjustment, ACEI/ARB exposure was not associated with testing positive for COVID-19 (pooled 
adjusted OR 1.01, 0.93 to 1.10), being hospitalized (OR 1.16, 0.80 to 1.68), having severe disease (1.04, 
0.76 to 1.42), or all-cause mortality (0.86, 0.64 to 1.15). Similarly, subgroup analyses involving only 
hypertensive patients revealed that ACEI/ARB exposure was not associated with being hospitalized 
(OR 0.84, 0.58 to 1.22), disease severity (OR 0.88, 0.68 to 1.14) or all-cause mortality (OR 0.77, 0.54 to 
1.12) while it decreased the length of hospitalization (mean difference -0.71, -1.11 to -0.30 days). After 
adjusting for relevant covariates, other cardiovascular drug classes were mostly not found to be 
associated with poor COVID-19 clinical outcomes. However, the validity of these findings is limited by 
a high level of heterogeneity in terms of effect sizes and a serious risk of bias, mainly due to 
confounding in the included studies. 
CONCLUSION 
Our comprehensive review shows that ACEI/ARB exposure is associated with COVID-19 outcomes such 
as susceptibility to infection, severity, and hospitalization in unadjusted analyses. However, after 
adjusting for potential confounding factors, this association is not evident.  Patients on cardiovascular 
drugs should continue taking their medications as currently recommended. Higher quality evidence in 
the form of randomized controlled trials will be needed to determine any adverse or beneficial effects 
of cardiovascular drugs. 
PRIMARY FUNDING SOURCE 
None 
SYSTEMATIC REVIEW REGISTRATION 
PROSPERO (CRD42020191283) 
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Coronavirus disease 2019 (COVID-19) was first reported on 8 December 2019 in Wuhan, Hubei 
province, China.1 It is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which 
infects cells through the human angiotensin-converting enzyme 2 (ACE2) receptor.2 It was designated 
a pandemic by the World Health Organization on 11 March 20203 and has since affected 188 countries, 
more than 31 million patients and led to over 957,000 deaths (as of 20 September 20204).  To put it 
into context, cardiovascular diseases such as ischemic heart disease, stroke and heart failure remain 
the leading causes of global deaths, being responsible for an estimated 17·8 million deaths in 2017.5 
The interaction between COVID-19 and cardiovascular disease appears complex and bi-directional 
with cardiovascular disease increasing susceptibility to SARS-CoV-2 infection or COVID-19 severity and 
at the same time COVID-19 causing injury to the cardiovascular system in some patients.6-9 
Consequently, the relationship between COVID-19 and cardiovascular drugs is of interest because: a) 
patients with increased susceptibility to SARS-CoV-2 infection may be taking these drugs, b) they may 
alleviate cardiovascular injury caused by COVID-19, and c) cardiovascular drugs such as  angiotensin-
converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may play a direct role in 
COVID-19 pathology.2  
Recent systematic reviews and/or meta-analyses10-21 have characterized the relationship between 
COVID-19 outcomes (such as severity and mortality) and cardiovascular drugs. These reviews have, 
however, been limited in scope in terms of the COVID-19 outcomes and cardiovascular drugs studied. 
For example, most have focused on ACEIs and ARBs given their interaction with the ACE2 receptor 
that facilitates SARS-CoV-2 entry into cells.2 However, being a novel disease, a lot is still unknown 
about COVID-19 which makes a broader systematic review (in terms of the drugs studied) necessary. 
Moreover, there are emerging reports that other drug classes such as anticoagulants, calcium channel 
blockers and statins could be beneficial.22-25 Additionally, many cardiovascular disease patients are on 
combination therapies and a broader review may facilitate understanding of the interplay between 
the different classes of cardiovascular drugs. Lastly, evidence in this field is rapidly evolving which 
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means that recently published reviews soon become outdated. To provide more comprehensive and 
up-to-date evidence, we have conducted a systematic review and meta-analysis to evaluate all the 
current evidence on the influence of cardiovascular drugs on COVID-19 clinical outcomes. Due to the 
rapidly evolving nature of this field, we will periodically update this baseline review for up to two years 
to reflect emerging evidence. 
 
METHODS 
A predefined protocol (PROSPERO: CRD42020191283), based on the principles of the Cochrane 
Handbook for Systematic Reviews of Interventions26 with living systematic review considerations27 28 
was followed. This report adheres to the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement29 (Table S1). 
Identification of studies 
A final search of the University of Liverpool’s DISCOVER platform (which links, through EBSCOhost, to 
sources from >500 databases including MEDLINE, Google Scholar, Scopus, the Web of Science and 
Cochrane Central Register of Controlled Trial libraries) was undertaken on 31st July 2020 using medical 
subject headings and text words related to “cardiovascular drugs” and “COVID-19” (Text S1). A 
separate MEDLINE search (Text S1) was conducted to ensure that the DISCOVER search was retrieving 
all eligible records. Lists of references from the identified studies and previous systematic reviews 
were hand-searched to identify additional eligible articles. Preprint servers (bioRxiv and medRxiv, Text 
S1), COVID-19 specific databases (such as the COVID-19 Clinical Trials registry and the World Health 
Organization database of COVID-19 publications), other registries/results databases (such as 
ClinicalTrials.gov and the International Clinical Trials Registry Platform) and grey literature were also 
searched to identify further eligible studies. After this baseline review is published, monthly searches 
will be conducted in the major bibliographic databases using the DISCOVER platform, with quarterly 
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searches applying to the other sources (including additional preprint servers such as Authorea.com, 
Preprints from Lancet, and Preprints.org). 
Selection criteria 
Both observational (e.g. cohorts/case-series and case-control studies) and interventional (e.g. 
randomised controlled trials) studies investigating the association between cardiovascular drugs and 
COVID-19 were included. Cardiovascular drugs were defined as those found in Chapter 2 
(“Cardiovascular system”) of the British National Formulary30 while COVID-19 clinical outcomes 
included those outlined below. Unless translated text could be obtained, non-English studies were 
excluded. 
Outcomes 
COVID-19 clinical outcomes included susceptibility to infection, disease severity (Text S2), 
hospitalization, hospitalization length, and all-cause mortality. 
Data extraction  
Two reviewers (IGA for DISCOVER and SP for MEDLINE) independently screened titles and abstracts of 
the retrieved bibliographic records according to eligibility. Where no abstract was available, the full 
text was obtained unless the article could be confidently excluded by its title alone. Full texts of 
potentially eligible studies were retrieved, a data extraction form developed and piloted in a subset 
of ten randomly selected papers and used to extract relevant information (related to study design, 
patient characteristics, cardiovascular drugs, COVID-19 outcomes, and study quality). Data from all 
eligible studies were extracted (Text S3 for more details) and summarized by one reviewer (IGA). As a 
quality control measure, a second reviewer (SP or RT) independently extracted and evaluated half the 
records to ascertain consistency. Any disagreements were resolved by consensus. 
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Assessment of study quality 
To assess the quality of each included study estimate, the revised Cochrane risk-of-bias tool for 
randomized trials31 and ROBINS-I (Risk Of Bias In Non-randomised Studies - of Interventions) tool for 
non-randomized studies32 were used. When applying ROBINS-I, we bore in mind that our aim was to 
quantify the effect of starting and adhering to the intervention under study on our outcomes, and so  
co-interventions such as other cardiovascular drugs, steroids, antivirals or procedures like mechanical 
ventilation that could differ between intervention groups and so could impact the outcomes were 
considered. Based on several systematic reviews of risk factors for COVID-19 outcomes,8 33-44 the 
confounding domains we thought relevant to all or most studies included age, race, gender, 
cardiovascular comorbidities (including hypertension, diabetes, and obesity), smoking and clinical 
setting/location.  
Data synthesis 
Where ≥ 2 studies reporting on the same exposure-outcome combination were reported, effect 
estimates were pooled by way of random-effects meta-analyses using R version 3.6.145 (R meta 
package46). Odds ratios and mean differences (with 95% confidence intervals) were generated for 
dichotomous and continuous outcomes, respectively. Both unadjusted (or in the case of binary 
outcomes, count data, which is preferred to unadjusted odds ratios as it provides more reliable 
estimates47) and adjusted estimates were extracted and pooled separately. Where there was more 
than one adjusted estimate, the estimate adjusting for the most covariates was preferred. Since 
different studies adjust for different covariates, we did not limit our inclusion criteria to a given set of 
covariates. Where median values and ranges/interquartile ranges were provided (for example for 
length of hospitalization), they were used to estimate the mean values and standard deviations.48 
Where necessary, means and standard deviations were combined using formulae available in the 
Cochrane Handbook.49 Forest plots were prepared for each exposure-outcome combination. Studies 
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that could not be pooled due to being the only ones reporting on an exposure-outcome combination 
were also included as part of qualitative synthesis. 
Heterogeneity measures 
The magnitude of inconsistency in the study results was assessed by visually examining forest plots 
and considering the I2 statistic.26 50 Arbitrarily-defined categories of heterogeneity were: I2 <30 %, low; 
I2 = 30–70 %, moderate; and I2 >70 %, high. Potential sources of heterogeneity were explored during 
the subgroup analyses (see below). 
Publication bias 
Where enough (≥10) studies were available for a given exposure-outcome combination, publication 
bias was assessed using the linear regression test of funnel plot asymmetry (Egger’s test, implemented 
using the metabias function in the R meta package46). A p-value <0.1 was considered to suggest the 
presence of publication bias. When asymmetry was suggested by a visual assessment, we performed 
exploratory analyses to investigate and adjust for it (trim and fill analysis) using the trimfill function (R 
metafor package51). 
Sensitivity and subgroup analyses 
Due to the need to provide results in real-time, many COVID-19 studies are being directly uploaded to 
preprint servers and/or undergoing rapid peer review. Therefore, in addition to a robust quality 
assessment, we conducted sensitivity analyses in which prominent/outlier studies were excluded to 
identify those studies whose retraction would significantly alter the pooled estimates. Prominent 
studies were identified through visual examination of the forest plots (criteria including accorded 
weights and whether individual estimates were consistent with other study estimates). Random 
effects meta-regression (Text S4) was conducted to both explore heterogeneity and inform sub-group 
analyses. Where possible, sub-group analyses based on drug sub-classes were also conducted. 
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Confidence in cumulative evidence 
The strength of the body of evidence and the quality and strength of recommendations was assessed 
according to the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) 
criteria.52 53 
Review updating 
After each monthly search, new evidence will be briefly summarized unless it changes the nature or 
strength of the conclusions, in which case a major update will be performed. The COVID-19 situation 
is extremely dynamic, and it is not possible to tell when we will be transitioning out of the living 
systematic review mode (updating for up to two years planned). The review scope and methods will, 
however, be reviewed at least once a year.  
 
RESULTS 
Study selection and characteristics 
Of the 23,427 titles screened, 178 and 175 studies were included in the qualitative and quantitative 
syntheses respectively (Figure 1). The characteristics of the included studies are shown in Table S2. 
Out of the 178 studies, more than a third (n = 67, 38%) were preprints. Most studies (n = 163, 92%) 
had a cohort/case series design with 14 (8%) being case-control studies. Only one (<1%) study was an 
open-label randomized control trial; however, it conducted a retrospective/non-pre-specified interim 
analysis of its currently recruited trial participants. The most commonly reported drug exposure was 
with angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) (ACEI/ARB), 
which therefore became the main focus.  
The summary risk of bias assessment for ACEI/ARB exposure is shown in Figure S1 (unadjusted 
estimates, all five outcomes). All studies had serious risks of bias, mainly driven by confounding (only 
counts/unadjusted estimates considered, with no adjustment for potential confounders) and 
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inappropriate selection of participants into the study (selection into the study was related to ACEI/ARB 
exposure and severity/hospitalization/mortality outcomes). The risk of bias in classification of 
interventions was generally considered low because of the chronic nature of most drug exposures 
while there was little information to assess the risk of bias due to deviations from intended 
interventions (we aimed to quantify the effect of starting and adhering to the intervention as 
explained under the methods section, although information on adherence was rarely reported). 
Although we did not examine each study’s individual analysis plan, the risk of bias due to missing data 
was generally considered to be low. We also considered the risk of bias in outcome measurement to 
be low, except for the susceptibility to infection outcome in which about 46% of the studies were at 
risk of differential misclassification (i.e. due to low testing rates, some participants considered 
negative could have been unknown COVID-19 cases). Although it could not be ruled out, bias during 
the selection of the reported result was considered moderate since in the primary meta-analyses the 
raw count data was used to calculate effect estimates. At least one of the first two domains was rated 
serious for all estimates which implied that the overall risk of bias rating for all studies had to be rated 
‘serious’. Because all estimates were rated as having a serious risk of bias, no sensitivity analyses based 
on methodological rigor were performed (the risk of bias assessments for all individual estimates are 
shown in the corresponding forest plots). 
Meta-analysis  
Table 1, Tables S3-S27 and Figures S2-S60 summarise the pooled estimates for the associations 
between all cardiovascular drug exposures and the various COVID-19 clinical outcomes. The text 
below is focused on the most reported drug (ACEI/ARB) exposure. 
Susceptibility to infection 
Thirty-one studies reported count data and/or crude odds ratios (OR) for the association between 
ACEI/ARB exposure and susceptibility to infection (Figure S2). Seven studies were removed to 
minimize the inclusion of studies with overlapping data. The primary meta-analysis (24 studies) 
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revealed that ACEIs/ARBs were associated with higher odds of testing positive for COVID-19 (pooled 
unadjusted OR 1.15, 95% CI 1.02 to 1.30, Figure 2). Heterogeneity was high (I2=93%) and could be 
explained by country (China versus other) and study design (multicentre vs single-centre, cohort/case 
series vs case-control) (Table S3). The pooled estimate was no longer statistically significant when 
analysis was restricted to only Chinese studies (n = 2), multicentre studies (n = 14), and case-control 
studies (n = 8) (Figure S2). The linear regression test of funnel plot asymmetry (Egger’s test, p = 0.89) 
was not significant (funnel plot in Figure S3). Six studies reported adjusted or propensity score–
weighted odds ratios (pooled adjusted OR 1.01, 95% CI 0.93 to 1.10, I2=0%) while two studies reported 
adjusted hazards ratios (pooled adjusted HR 1.05, 95% CI 0.92 to 1.20, I2=0%) (Figure S2). Other 
cardiovascular drug classes included anticoagulants, antiplatelets, beta-blockers, calcium channel 
blockers, class III anti-arrhythmics (specifically amiodarone), diuretics and lipid modifying drugs. 
Except for beta-blockers and diuretics (unadjusted estimates), none of the other cardiovascular drug 
exposures (including ACEIs and ARBs assessed separately) were associated with susceptibility to 
infection as detailed in Table 1. 
Hospitalization  
Twenty-three studies explored the association between being hospitalized and being on ACEIs/ARBs 
(Figure S12). When three studies were excluded to reduce potentially overlapping data, ACEIs/ARBs 
were associated with higher odds of being hospitalized (pooled unadjusted OR 2.25, 95% CI 1.70 to 
2.98, I2=91%, Figure 2). Heterogeneity could be explained by study-level mean/median ages and the 
proportion of patients with hypertension (Table S7). Four studies included only hypertensive patients 
and for these, the pooled estimate lost statistical significance (Figure 3). We did not conduct sub-group 
analyses based on age because no two studies included patients of a unique age category. Publication 
bias assessment for the 20 studies did not reveal funnel plot asymmetry (Figure S13, Egger’s test p-
value = 0.13). The pooled adjusted odds ratio (6 studies) was not statistically significant at 1.16 (95% 
CI 0.80 to 1.68, I2=53%), a result which was similar to the pooled adjusted hazards ratio (1.00, 95% CI 
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0.87 to 1.14, I2=0%, 2 studies) (Figure S12). Other cardiovascular drugs were also associated with 
higher odds of being hospitalized in unadjusted, but not adjusted, estimates (Table 1). 
Hospitalization length 
Twelve studies reported length of hospitalization (Figure S20) and for 11 of these without potentially 
overlapping datasets, ACEIs/ARBs were not significantly associated with longer hospitalization length 
(mean difference -0.45, 95% CI -1.33 to 0.43 days, I2=30%, Figure 2). When one study attributed 34% 
of the weight was excluded in a sensitivity analysis, the results were similar (mean difference -0.44, 
95% CI -1.66 to 0.77 days, I2=32%). Heterogeneity was moderate and explainable by both age and 
proportion of patients with hypertension (Table S10). When 9 studies that included only hypertensive 
patients were pooled, ACEIs/ARBs were associated with shorter hospitalization length although this 
benefit was small. Egger’s test was not statistically significant (p = 0.94, funnel plot in Figure S21). This 
outcome was not assessed for other cardiovascular drug exposures. 
Severity 
Seventy-six studies reported the association between ACEIs/ARBs and severity outcomes (Figure S22). 
Sixteen studies were excluded due to having potentially overlapping data which resulted in a primary 
meta-analysis of 60 studies in which ACEIs/ARBs were associated with higher odds of severe disease 
(pooled OR 1.50, 95% CI 1.27 to 1.77, I2=81%, Figure 2). Heterogeneity could be explained by country, 
study setting, sample size, study-level mean/median ages, and the proportion of patients with 
hypertension and diabetes mellitus (Table S11). Sub-group analyses based on country (South Korea 
versus other), in-patient study setting, and the proportion of patients with diabetes mellitus arrived 
at similar conclusions while the pooled estimates were no longer significant when only Chinese studies 
or hypertensive cohorts were pooled (Figure 3, Figure S22). Publication bias assessment for the 60 
studies revealed funnel plot symmetry (Figure S23, Egger’s test p = 0.15). Adjusted odds ratios were 
obtained from 18 studies (pooled adjusted OR 1.04, 95% CI 0.76 to 1.42, I2=65%) while hazard ratios 
were obtained from 4 studies (pooled adjusted HR 0.98, 95% CI 0.72 to 1.33, I2=68%) (Figure S22). 
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Except for antiplatelet exposure, other cardiovascular drugs were associated with higher odds of 
severe disease in the unadjusted estimates, with statistical significance being lost when adjusted 
estimates were considered (Table 1).   
All-cause mortality 
Seventy-three studies reported the association between ACEI/ARB exposure and all-cause mortality 
(Figure S40). Because some studies had potentially overlapping datasets, only 40 were included in the 
primary meta-analysis with ACEIs/ARBs not being associated with higher odds of all-cause mortality 
(pooled OR 1.25, 95% CI 0.98 to 1.58, Figure 2). Heterogeneity was high (I2=85%) and could be 
accounted for by country, sample size, study-level mean/median ages, and the proportion of patients 
with hypertension (Table S19). The direction of the pooled estimate was reversed and was statistically 
significant in 12 China-only studies (Figure S40) whilst when restricting the analysis to hypertensive 
cohorts only (n = 18), the result remained non-significant (Figure 3). Egger’s test was not statistically 
significant (p = 0.20, funnel plot in Figure S41). The pooled adjusted odds ratio (13 studies) was 0.86 
(95% CI 0.64 to 1.15, I2=4%) while the pooled adjusted hazards ratio (10 studies) was 0.94 (95% CI 0.79 
to 1.13, I2=29%) (Figure S40). Except for anticoagulants, other cardiovascular drugs were associated 
with higher odds of all-cause mortality in the unadjusted estimates. Statistical significance was lost for 
ACEIs, ARBs, anticoagulants, calcium channel blockers, and lipid-modifying drugs when adjusted ORs 
were pooled. When adjusted hazards ratios were considered, ACEIs, ARBs, calcium channel blockers 
and diuretics were not associated with all-cause mortality while lipid-modifying drugs (statins) 
decreased the odds of dying (HR 0.67, 95% CI 0.47 to 0.96, I2=83%, Table 1). 
 
DISCUSSION 
We have conducted a systematic review and meta-analysis to evaluate the current evidence on the 
influence of cardiovascular drugs on five COVID-19 clinical outcomes. The most reported drug classes 
were angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) with 
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ACEI/ARB exposure being associated with higher odds of testing positive for COVID-19, which 
contradicts a previous estimate by Zhang et al. (0.99, 95% CI, 0.95 to 1.04).10 Our study, which included 
24 studies for this outcome, is however more comprehensive than Zhang et al.’s  which included only 
3 studies for the same outcome. Among COVID-19 patients, ACEI/ARB exposure was associated with 
being hospitalized, having severe disease but not hospitalization length or all-cause mortality. Diaz-
Arocutipa et al.14 who explored these four outcomes reported similar results for hospitalization length 
(mean difference -0.96 days, 95%CI -2.50 to 0.57, n = 5 studies) and mortality (OR 1.11, 95%CI 0.77-
1.60, n = 22 studies) but not for being hospitalized (OR 1.83, 95%CI 0.95-3.52, n = 4 studies) or having 
severe disease (OR 0.79, 95%CI 0.59-1.07, n = 18 studies) – differences we again attribute to our review 
being bigger in terms of the number of studies included. With a higher rate of hospitalization and more 
severe disease, one would respectively expect longer hospital stay and increased mortality, which 
makes our results seem counter intuitive. However, the length of hospitalization outcome excluded 
patients who died or those who were still hospitalized by the time of analysis, which may have 
contributed to the observed discrepancy. It is also important to note that these results are from 
pooling unadjusted estimates which did not account for confounding factors such as cardiovascular 
comorbidities. For instance, because hypertension might necessitate ACEI/ARB use, and hypertension 
contributes to poor COVID-19 clinical outcomes,8 36-39 estimates that do not adjust for hypertension 
might be spuriously elevated as seen above (an example of “confounding by indication”). Indeed, 
when subgroup analyses that included only hypertensive patients were conducted, ACEI/ARB 
exposure was no longer associated with being hospitalized or having severe disease. Lastly, co-
interventions such as steroids and remdesivir that could influence these results could not be 
accounted for since studies rarely reported these co-interventions and stratified them by 
cardiovascular drug exposure. 
We also reported pooled adjusted estimates in which ACEI/ARB exposure was not associated with 
higher odds of testing positive for COVID-19, being hospitalized, having severe disease, or all-cause 
mortality. Diaz-Arocutipa et al.14 reported similar estimates for all-cause mortality (adjusted hazards 
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ratio 0.83, 95%CI 0.49 to 1.38, n = 3 studies) but not severity (adjusted OR 0.56, 95%CI 0.37 to 0.87, n 
= 4 studies). Although pooling adjusted estimates can protect against the effect of confounders 
present in unadjusted estimates, these pooled adjusted estimates should still be cautiously 
interpreted since many did not include adjustment for important confounders, and odds/hazard ratios 
that adjust for different sets of covariates may not be comparable.47 Further, adjusted odds/hazards 
ratios are expected to be further from zero (the “non-collapsibility” of effect estimates).54  
Regarding other cardiovascular drug classes, this is the first review to be broad in this context (most 
previous reviews have focused solely on ACEIs/ARBs) with most other drugs not being associated with 
poor COVID-19 clinical outcomes in the pooled adjusted estimates.  One key result is that lipid 
modifying drugs (statins in particular) appear to protect against all-cause mortality based on the 
adjusted hazards ratios, as has recently been reported.55 However, the number of included studies (n 
= 4) was small and the adjusted odds ratios were not statistically significant. The potential mechanisms 
in which cardiovascular drugs can influence COVID-19 outcomes have been previously discussed.6-9 22-
25  
Limitations of this review 
For most of the  meta-analyses, heterogeneity in effect estimates was high, which is similar to previous 
observations.10 12-14 17 18 21 Consequently, following GRADE rating,52 53 all estimates with high 
heterogeneity (I2 >70) were downgraded by one level (high to moderate certainty rating). Additionally, 
almost all estimates were ranked to be at a serious risk of bias. This differs from previous reviews in 
which many studies were considered to have low to moderate risk of bias,10-18 20 21 a contradiction we 
attribute to the risk of bias assessment tools used (whereas we used the ROBINS-I [Risk Of Bias In Non-
randomised Studies – of Interventions] tool for non-randomized studies,32 other reviews used the 
Newcastle Ottawa Scale).  Again following GRADE52 53 recommendations, the evidence certainty rating 
was downgraded by one level for estimates with a serious risk of bias (from high to moderate or from 
moderate to low). Despite our comprehensive search strategy and to facilitate timely publication, we 
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did not contact study authors for data that was required to enable meta-analysis but not reported in 
the published paper, and therefore did not include studies that could potentially be eligible. We were 
also unable to include many studies from some preprint servers such as Authorea.com, Preprints from 
Lancet, and Preprints.org. We were however cognizant of the fact that this is a living systematic review 
and any studies that we excluded due to data needed for meta-analysis not being reported, or that 
we missed in our initial searches may be included in subsequent updates. We also included several 
preprint publications that have not been certified by peer review. This we felt necessary since many 
COVID-19 studies are being first published as preprints and we will be reassessing the preprints that 
will be peer-reviewed in future updates. We tried to exclude potentially overlapping data – however, 
we may have missed some overlapping data or inadvertently excluded non-overlapping data. The 
overall low contributions/assigned weights of the individual studies make the reported estimates 
robust to these errors. We also relied on single-reviewer extraction for half the studies, which could 
introduce bias from simple errors.  Any new information/inconsistencies that come to our attention 
will be incorporated in subsequent reviews. Lastly, we could not explore the interplay of the various 
cardiovascular drugs because the number of studies for many drug classes was small. Once more, 
preferably high-quality, studies become available, we will compare how the different drug classes 
perform in combination and against each other (for example propensity score stratified HRs suggest 
that ACEIs/ARBs combined with other drugs are similar to calcium channel blockers/thiazides (HR 1.01, 
95% CI 0.90 to 1.15) and ACEI combinations are more protective than ARB combinations (HR 0.88, 95% 
CI 0.79 to 0.99) in terms of susceptibility to infection56).  
Conclusions 
Low- to moderate-certainty evidence suggests that cardiovascular drugs are not associated with poor 
COVID-19 clinical outcomes in high-risk patients such as those with hypertension. High quality 
evidence in the form of randomized controlled trials is urgently required and will be incorporated in 
updates of this review as soon as it is available (several trials are currently ongoing such as the 3 
interventional phase III studies listed on ClinicalTrials.gov for Losartan [identifiers: NCT04343001, 
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NCT04328012, NCT04349410], as of 30 August 2020). A better understanding of the interactions 
between cardiovascular drugs and COVID-19 pathology is required at cellular and molecular level to 
resolve the biological plausibility arguments that support both harm and benefit from ARB/ACEI 
exposure.6-9 As we await further evidence, patients on cardiovascular drugs should continue taking 
their medications as is recommended worldwide for ARBs/ACEIs.  
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Figure 1. PRISMA Flow Chart of Included Studies.  
Figure 2. Forest plots for associations between COVID-19 outcomes and being on an angiotensin-
converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB). Gnavi and Morales studies 
each provided two separate cohorts. *Estimates assume that none of the patients are taking both 
ACEIs and ARBs. Risk of bias legend. A = risk of bias due to confounding, B = risk of bias in selection of 
participants into the study, C = risk of bias in classification of interventions, D = risk of bias due to 
deviations from intended interventions, E = risk of bias due to missing data, F = risk of bias in 
measurement of outcomes, G = risk of bias in selection of the reported result, H = overall risk of bias. 
Color codes. Colour codes. Red = serious, yellow = moderate, green = low, grey = unclear. CDD = 
circulatory diseases/diabetes population, CUIMC = Columbia University Irving Medical Center, HY = 
hypertension population. 
Figure 3. Forest plots for associations between COVID-19 outcomes and being on an angiotensin-
converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) – only hypertensive 
patients included. Risk of bias legend. A = risk of bias due to confounding, B = risk of bias in selection 
of participants into the study, C = risk of bias in classification of interventions, D = risk of bias due to 
deviations from intended interventions, E = risk of bias due to missing data, F = risk of bias in 
measurement of outcomes, G = risk of bias in selection of the reported result, H = overall risk of bias. 
Color codes. Colour codes. Red = serious, yellow = moderate, green = low, grey = unclear. 
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Table 1. Summary results for associations between cardiovascular drug exposure and COVID-19 outcomes*. 
Outcome Exposure All 
studies 







Unadjusted estimates (95% 
CI), heterogeneity (I2) 






ACEI/ARB 31 24 1,362,182 OR 1.15 (1.02; 1.30), I2=93% Country, study design 
China-only (n=2): OR 0.70 (0.35; 1.40), I2=70% 
Not in China (n=22): OR 1.19 (1.06; 1.35), I2=93%  
Single centre (n=10): OR 1.51 (1.36; 1.69), I2=0% 
Multicentre (n=14): OR 1.04 (0.91; 1.20), I2=95% 
Cohorts (n=16): OR 1.33 (1.15; 1.55), I2=89% 
Case-controls (n=8): OR 0.91 (0.75; 1.11), I2=94% 
0.89 OR (n=6): 1.01 (0.93; 1.10), I2=0% 
HR (n=2): 1.05 (0.92; 1.20), I2=0% 
Figures 2, S2-S3; 
Table S3 
ACEI 20 17 818,018 OR 1.09 (0.97; 1.23), I2=84% Study design 
Single centre (n=5): OR 1.48 (1.25; 1.75), I2=0% 
Multicentre (n=12): OR 1.02 (0.89; 1.17), I2=87% 
0.76 OR (n=9): 0.97 (0.87; 1.09), I2=0% Figures S4-S5; 
Table S4 
ARB 20 17 823,654 OR 1.11 (0.96; 1.28), I2=90% Publication status, study design 
Peer-reviewed (n=9): OR 1.24 (1.07; 1.43), I2=79% 
Preprints (n=8): OR 0.96 (0.80; 1.16), I2=84% 
Single centre (n=5): OR 1.42 (1.23; 1.63), I2=0% 
Multicentre (n=12): OR 1.03 (0.87; 1.21), I2=93% 
Cohorts (n=10): OR 1.30 (1.13; 1.51), I2=72% 
Case-controls (n=7): OR 0.91 (0.74; 1.12), I2=92% 
0.83 OR (n=9): 0.90 (0.65; 1.24), I2=89%; 
when one outlier study removed, OR 
1.04 (0.96; 1.12), I2=10% 
Figures S6-S7; 
Table S5 
Anticoagulant 9 9 333,417 OR 1.17 (0.98; 1.41), I2=86% NA NA OR (n=2): 0.86 (0.47; 1.56), I2=95% Figures S8-S9 
Antiplatelet 6 6 417,227 OR 1.07 (0.85; 1.35), I2=93% NA NA OR (n=3): 0.78 (0.32; 1.93), I2=87% Figures S8-S9 
Beta blocker 10 9 1,744,871 OR 1.15 (1.02; 1.29), I2=84% NA NA OR (n=5): 0.94 (0.84; 1.06), I2=20% Figures S8-S9 




3 3 102,242 OR 0.65 (0.17; 2.47), I2=92% NA NA NA Figure S8 
Diuretics 9 9 5,609,843 OR 1.37 (1.16; 1.62), I2=96% Loop diuretics (n=4): OR 1.92 (1.35; 2.71), I2=97% 
Thiazides (n=5): OR 1.14 (0.88; 1.47), I2=95% 
Other‡ (n=3): OR 1.80 (1.47; 2.21), I2=45% 
NA OR (n=5): 0.82 (0.53; 1.27), I2=83% Figures S8-S9 
Lipid modifying 
drug 
11 11 708,933 OR 1.16 (0.98; 1.38), I2=94% COVID-1 testing, diabetes mellitus 
All tested (n=4): OR 0.96 (0.70; 1.31), I2=86% 
Not all tested (n=7): OR 1.28 (1.10; 1.49), I2=88% 
Statins (n=7): OR 1.25 (0.80; 1.95), I2=93% 




ACEI/ARB 23 20 27,413 OR 2.25 (1.70; 2.98), I2=91% Age, hypertension  
All hypertensive (n=4): OR 0.84 (0.58; 1.22), I2=66% 
0.13 OR (n=6): 1.16 (0.80; 1.68), I2=53% 
HR (n=2): 1.00 (0.87; 1.14), I2=0% 
Figures 2-3, S12-
S13; Table S7 
ACEI 15 12 11,159 OR 2.51 (1.44; 4.36), I2=93% None 0.85 OR (n=6): 0.78 (0.47; 1.28), I2=73% 
HR (n=2): 1.04 (0.64; 1.68), I2=84% 
Figures S14-S15; 
Table S8 
ARB 15 12 11,159 OR 2.16 (1.16; 4.00), I2=94% Age, hypertension 
All hypertensive (n=3): OR 0.77 (0.46; 1.29), I2=39% 
0.63 OR (n=6): 1.09 (0.67; 1.77), I2=51% 
HR (n=2): 1.07 (0.79; 1.43), I2=55% 
Figures S16-S17; 
Table S9 
Anticoagulants 7 6 12,630 OR 3.16 (1.66; 6.01), I2=89% NA NA NA Figure S18 
Antiplatelets 5 4 12,367 OR 3.27 (1.85; 5.76), I2=87% NA NA NA Figure S18 
Beta blocker 7 7 14, 158 OR 2.47 (1.35; 4.55), I2=93% NA NA OR (n=3): 0.86 (0.38; 1.96), I2=77% Figures S18-S19 
CCB 6 5 13,135 OR 2.38 (1.42; 3.98), I2=87% NA NA OR (n=3): 1.16 (0.83; 1.63), I2=0% Figures S18-S19 
Diuretic 5 5 34,774 OR 3.09 (1.64; 5.82), I2=97% NA NA OR (n=4): 1.26 (0.90; 1.76), I2=0% Figures S18-S19 
Lipid modifying 
drug 
5 5 13,093 OR 3.88 (2.92; 5.17), I2=72% NA NA OR (n=2): 1.00 (0.31; 3.21), I2=86% Figures S18-S19 
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Table 1. Continued. 
Outcome Exposure All 
studies 







Unadjusted estimates (95% 
CI), heterogeneity (I2) 






ACEI/ARB 12 11 2,510 MD -0.45 (-1.33; 0.43) days, 
I2=30% 
Age, hypertension 
All hypertensive (n=9): MD -0.71 (-1.11; -0.30) days, I2=0% 
0.94 NA Figures 2-3, S20-
S21; Table S10 
Severity ACEI/ARB 76 60 45,394 OR 1.50 (1.27; 1.77), I2=81% Country, setting, sample size, age, hypertension, 
diabetes mellitus 
China-only (n=14): OR 0.97 (0.71; 1.33), I2=58% 
Not in China (n=46): OR 1.70 (1.41; 2.04), I2=82% 
South Korea-only (n=2): OR 4.04 (2.28; 7.16), I2=0% 
Not in S.Korea (n=58): OR 1.45 (1.23; 1.72), I2=81%All 
inpatient (n=48): OR 1.29 (1.12; 1.49), I2=61% 
All hypertensive (n=22): OR 0.88 (0.68; 1.14), I2=77% 
All diabetic (n=2): OR 1.27 (1.01; 1.60), I2=0% 
0.15 OR (n=18): 1.04 (0.76; 1.42), I2=65% 
HR (n=4): 0.98 (0.72; 1.33), I2=68% 
Figure 2, 3, S22-
S23; Table S11 
ACEI 35 32 25,962 OR 1.67 (1.33; 2.10), I2=77% Setting, age, hypertension, diabetes mellitus 
All inpatient (n=24): OR 1.27 (1.08; 1.50); I2=22% 
All hypertensive (n=11): OR 0.89 (0.70; 1.13), I2=40% 
0.37 OR (n=10): 0.72 (0.46; 1.13), I2=53% 
HR (n=2): 1.18 (1.07; 1.30), I2=0% 
Figures S24-S25; 
Table S12 
ARB 35 32 26,106 OR 1.48 (1.19; 1.85), I2=79% Country, setting, sample size, age, hypertension, 
diabetes mellitus 
China-only (n=5): OR 0.79 (0.48; 1.32), I2=66% 
Not in China (n=27): OR 1.69 (1.34; 2.13), I2=78% 
USA-only (n=9): OR 2.08 (1.26; 3.43), I2=89%Not in 
USA (n=23): OR 1.28 (1.01; 1.63), I2=69% 
All inpatient (n=25): OR 1.23 (1.04; 1.46), I2=34% 
All hypertensive (n=12): OR 0.99 (0.81; 1.21), I2=39% 
0.28 OR (n=12): 1.12 (0.69; 1.82), I2=52% 
HR (n=2): 1.05 (0.74; 1.48), I2=61% 
Figures S26-S27; 
Table S13 
Anticoagulant 14 14 14,779 OR 1.99 (1.52; 2.62), I2=34% None 0.20 OR (n=2): 1.35 (0.80; 2.29), I2=0% Figures S28-S29; 
Table S14 
Antiplatelet 10 10 14,745 OR 1.39 (0.86; 2.24), I2=79% Sample size, diabetes mellitus, publication status 
Peer-reviewed (n=5): OR 0.73 (0.46; 1.15), I2=5% 
Preprints (n=5): OR 2.43 (1.70; 3.45), I2=56% 
0.004 OR (n=2): 0.70 (0.39; 1.25), I2=0% Figures S30-S32; 
Table S15 
Beta blocker 12 12 20,524 OR 1.63 (1.17; 2.27), I2=79% Sample size, age, gender, hypertension, diabetes 
mellitus 
All hypertensive (n=5): OR 0.98 (0.80; 1.20), I2=0% 
0.61 OR (n=5): 1.19 (0.54; 2.65), I2=46% Figures S33-S34; 
Table S16 
CCB 15 14 16,910 OR 1.55 (1.14; 2.09), I2=73% Country, sample size, age, hypertension, diabetes 
mellitus 
China-only (n=4): OR 1.03 (0.71; 1.48), I2=24% 
Not in China (n=10): OR 1.93 (1.40; 2.67), I2=65% 
All hypertensive (n=7): OR 1.26 (1.06; 1.49), I2=0% 
0.11 OR (n=6): 1.31 (0.62; 2.80), I2=66% Figures S35-S36; 
Table S17 
Diuretic 9 9 19,928 OR 1.33 (1.15; 1.53), I2=0% Loop diuretics (n=3): OR 1.66 (0.82; 3.37), I2=89% 
Thiazides (n=5): OR 1.33 (1.11; 1.59), I2=12% 
Other‡ (n=4): OR 1.20 (0.78; 1.85), I2=0% 
NA OR (n=5): 0.91 (0.65; 1.27), I2=0% Figures S37 
Lipid modifying 
drug 
16 15 17,155 OR 1.68 (1.18; 2.38), I2=83% Publication status, sample size, age, hypertension, 
diabetes mellitus 
Peer-reviewed (n=7): OR 1.22 (0.87; 1.72), I2=48% 
Preprints (n=8): OR 2.14 (1.48; 3.11), I2=71% 
0.72 OR (n=5): 1.63 (0.57; 4.65), I2=72% Figures S38-S39; 
Table S18 
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Table 1. Continued. 
Outcome Exposure All 
studies 







Unadjusted estimates (95% 
CI), heterogeneity (I2) 






ACEI/ARB 73 40 43,099 OR 1.25 (0.98; 1.58), I2=85% Country, sample size, age, hypertension 
China-only (n=12): OR 0.63 (0.46; 0.85), I2=0% 
Not in China (n=28): OR 1.54 (1.18; 1.99), I2=88% 
All hypertensive (n=18): OR 0.77 (0.54; 1.12), I2=68% 
0.20 OR (n=13): 0.86 (0.64; 1.15), I2=4% 
HR (n=10): 0.94 (0.79; 1.13), I2=29% 
Figures 2-3 S40-
S41; Table S19 
ACEI 30 20 32,601 OR 1.38 (1.03; 1.85), I2=79% Sample size, age, hypertension 
All hypertensive (n=6): OR 0.90 (0.79; 1.04), I2=0% 
0.73 OR (n=5): 0.80 (0.46; 1.38), I2=58% 
HR (n=5): 1.03 (0.90; 1.18), I2=0% 
Figures S42-S43; 
Table S20 
ARB 27 18 32,407 OR 1.43 (1.05; 1.93), I2=84% Sample size, age, hypertension 
All hypertensive (n=6): OR 0.97 (0.73; 1.29), I2=19% 
0.90 OR (n=4): OR 1.11 (0.94; 1.32), I2=51% 
HR (n=5): 1.05 (0.90; 1.22), I2=10% 
Figures S44-S45; 
Table S21 
Anticoagulant 24 17 17,687 OR 0.97 (0.48; 1.94), I2=96% Setting, sample size, gender 
All inpatient (n=13): OR 0.82 (0.56; 1.18), I2=71% 




Antiplatelet 16 13 14,634 OR 1.85 (1.08; 3.16), I2=91% Publication status, sample size, age, hypertension 
Peer-reviewed (n=10): OR 1.50 (1.02; 2.19), I2=48% 
Preprints (n=3): OR 4.99 (2.14; 11.64), I2=90% 
0.12 NA Figures S48-S49; 
Table S23 
Beta blocker 13 13 18,583 OR 2.16 (1.47; 3.20), I2=87% Sample size, age, hypertension 
All hypertensive (n=2): OR 1.64 (0.59; 4.54), I2=54% 
0.05 OR (n=2): 1.44 (1.19; 1.75), I2=0% Figures S50-S52; 
Table S24 
CCB 15 12 17,970 OR 1.43 (1.03; 1.99), I2=75% Sample size, age, hypertension, diabetes mellitus 
All hypertensive (n=4): OR 1.06 (0.74; 1.53), I2=11% 
0.04 OR (n=2): 0.86 (0.60; 1.24), I2=10% 
HR (n=2): 0.34 (0.04; 3.16), I2=84% 
Figures S53-S55; 
Table S25 
Diuretic 12 11 42,290 OR 3.45 (2.30; 5.18), I2=92% Publication status, country, setting, age, 
hypertension 
Peer-reviewed (n=9): OR 2.74 (1.82; 4.11), I2=81% 
Preprints (n=2): OR 7.43 (3.02; 18.28), I2=98% 
France-only (n=2): OR 1.40 (0.41; 4.80), I2=87% 
Not in France (n=9): OR 4.28 (2.84; 6.44), I2=91% 
Inpatient (n=8): OR 2.21 (1.55; 3.17), I2=63% 
Loop diuretics (n=5): OR 6.07 (3.09; 11.90), I2=94% 
Thiazides (n=5): OR 1.82 (0.90; 3.69), I2=93% 
Other‡ (n=5): OR 2.53 (1.33; 4.82), I2=74% 
0.18 OR (n=2): 1.55 (1.25; 1.91), I2=0% 





19 12 32,625 1.54 (1.09; 2.19), I2=90% None 
Statins (n=8): OR 1.41 (0.97; 2.04), I2=79% 
0.54 OR (n=4): 1.08 (0.68; 1.71), I2=33% 
HR (n=4): 0.67 (0.47; 0.96), I2=83% 
Figures S58-S59; 
Table S27 
Vasopressors 4 4 3,572 OR 10.24 (1.56; 67.40), I2=94% NA NA NA Figure S60 
*In terms of GRADE rating, all estimates were downgraded to moderate certainty due to a serious risk of bias for all. Estimates with heterogeneity (I2 >70) were further downgraded to low 
certainty. ‡Refers to potassium-sparing diuretics and aldosterone antagonists. Abbreviations: ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin receptor blocker, CCB = calcium 
channel blocker, HR = hazard ratio, MD = mean difference, NA = not applicable, OR = odds ratio. 
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